Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01418222 · ClinicalTrials.gov registry record · Phase 2
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT01418222 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 194 participants.
The verdict
NCT01418222, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.
Interventions
- DRUG Placebo
- DRUG FOLFOX regimen
- DRUG 5-FU
- DRUG leucovorin
- DRUG bevacizumab [Avastin]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2011-09-14 |
| Est. Completion | 2013-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01418222
The ClinicalTrials.gov registry entry for NCT01418222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01418222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01418222 about?
NCT01418222 is a clinical study titled "FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer". This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.
What is the current status of trial NCT01418222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2011-09-14. Estimated completion is 2013-03-18.
What interventions are being tested in trial NCT01418222?
The interventions under investigation include: Placebo (DRUG), FOLFOX regimen (DRUG), 5-FU (DRUG), leucovorin (DRUG), bevacizumab [Avastin] (DRUG).
Who is sponsoring clinical trial NCT01418222?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.